T
Tonix Pharmaceuticals Holding Corp (TNXP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$2.88
-0.13 (-4.32%)
Market Cap: $58.49M
Last updated: Nov 17, 2026 at 11:06 AM ET
Tonix Pharmaceuticals Holding Corp (TNXP) Valuation Multiples
Tonix Pharmaceuticals Holding (TNXP) trades at 1.2x sales and 0.3x book value. Its P/B of 0.3x is below its 5-year median of 0.5x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | N/A |
| Price to sales | 1.2x |
| Price to book | 0.3x |
| EV/FCF | 0.6x |
| PEG | N/A |
| FCF yield | -320.2% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 0.3x | 0.5x | N/A |
Valuation History
Over the 6 of the 10 year ends shown that have a P/B, its P/B ranged from 0.5x in 2024 to 45.3x in 2016.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $15.62 | 9.3x | 0.5x |
| 2024 | $32.98 | N/A | 0.5x |
| 2023 | $1,291.67 | N/A | N/A |
| 2022 | $7,808.49 | N/A | N/A |
| 2021 | $229,662.33 | N/A | 0.7x |
| 2020 | $433,385.72 | N/A | 1.4x |
| 2019 | $751,201.92 | N/A | N/A |
| 2018 | $14,125,164.37 | N/A | 5.1x |
| 2017 | $221,508,259.37 | N/A | N/A |
| 2016 | $301,829,080.37 | N/A | 45.3x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TNXP
Is TNXP stock overvalued?
GNG's valuation label for TNXP is Overvalued.
What is TNXP's price to sales ratio?
Tonix Pharmaceuticals Holding has a price to sales ratio of 1.2x.
TNXP pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors